Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting

被引:53
作者
Taussig, DC [1 ]
Davies, AJ [1 ]
Cavenagh, JD [1 ]
Oakervee, H [1 ]
Syndercombe-Court, D [1 ]
Kelsey, S [1 ]
Amess, JAL [1 ]
Rohatiner, AZS [1 ]
Lister, TA [1 ]
Barnett, MJ [1 ]
机构
[1] St Bartholomews Hosp, Dept Med Oncol, Div Haematol Oncol, London EC1A 7BE, England
关键词
D O I
10.1200/JCO.2003.02.057
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : To evaluate the use of reduced-intensity (RI) conditioning with allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical family donors in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients and Methods: Sixteen patients (median age, 54 years; range, 37 to 66 years) underwent RI-HSCT using a conditioning regimen of fludarabine 25 mg/m(2) daily for 5 days and either cyclophosphamide 1 g/m(2) daily for 2 days (14 patients) or melphalan 140 mg/m2 for 1 day (two patients). The median number of CD34(+) cells and CD3(+) cells infused per kilogram of recipient weight was 4.5 x 10(6) (range, 1.8 to 7.3 x 10(6) cells) and 2.9 x 10(8) (range, 0.1 to 9.6 x 10(8) cells), respectively. Results: There was no transplant-related mortality (TRM) within 100 days of HSCT. Grade 1 to 2 acute graft-versus-host disease (GVHD) occurred in three patients, but neither grade 3 nor grade 4 disease was observed. Chronic GVHD occurred in 10 patients. One patient had cytomegalovirus (CMV) reactivation but did not develop CMV disease. With a median follow-up of 26 months (range, 15 to 45 months), 11 patients are alive (nine in continuous complete remission and one in complete remission after a second transplantation), and five have died (four from disease progression and one from bone-marrow aplasia induced by cyclosporine withdrawal). The 2-year actuarial overall and event-free survival rates were 69% (95% confidence interval [Cl], 40% to 86%) and 56% (95% Cl, 30% to 68%), respectively. Conclusion: This strategy of RI-HSCT resulted in reliable engraftment with low incidence of acute GVHD and TRM. Durable remissions were observed in patients with MDS and AML consistent with a graft-versus-leukemia effect.
引用
收藏
页码:3060 / 3065
页数:6
相关论文
共 34 条
[1]  
ATKINSON K, 1990, BLOOD, V75, P2459
[2]   Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): Report of a workshop of the European Group for Blood and Marrow Transplantation (EBMT) [J].
Bacigalupo A. .
Bone Marrow Transplantation, 2000, 25 (8) :803-805
[3]   Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation [J].
Baurmann, H ;
Nagel, S ;
Binder, T ;
Neubauer, A ;
Siegert, V ;
Huhn, D .
BLOOD, 1998, 92 (10) :3582-3590
[4]   REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[5]   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[6]   Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies [J].
Corradini, P ;
Tarella, C ;
Olivieri, A ;
Gianni, AM ;
Voena, C ;
Zallio, F ;
Ladetto, M ;
Falda, M ;
Lucesole, M ;
Dodero, A ;
Ciceri, F ;
Benedetti, F ;
Rambaldi, A ;
Sajeva, MR ;
Tresoldi, M ;
Pileri, A ;
Bordignon, C ;
Bregni, M .
BLOOD, 2002, 99 (01) :75-82
[7]   A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies [J].
Couban, S ;
Simpson, DR ;
Barnett, MJ ;
Bredeson, C ;
Hubesch, L ;
Kang, HL ;
Shore, TB ;
Walker, IR ;
Browett, P ;
Messner, HA ;
Panzarella, T ;
Lipton, JH .
BLOOD, 2002, 100 (05) :1525-1531
[8]   Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [J].
de Witte, T ;
Hermans, J ;
Vossen, J ;
Bacigalupo, A ;
Meloni, G ;
Jacobsen, N ;
Ruutu, T ;
Ljungman, P ;
Gratwohl, A ;
Runde, V ;
Niederwieser, D ;
van Biezen, A ;
Devergie, A ;
Cornelissen, J ;
Jouet, JP ;
Arnold, R ;
Apperley, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (03) :620-630
[9]  
DEEG HJ, 1991, BONE MARROW TRANSPL, V7, P193
[10]   Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission [J].
Feinstein, LC ;
Sandmaier, BM ;
Hegenbart, U ;
McSweeney, PA ;
Maloney, DG ;
Gooley, TA ;
Maris, MB ;
Chauncey, TR ;
Bruno, B ;
Appelbaum, FR ;
Niederwieser, DW ;
Storb, RF .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (02) :281-288